Loading...
•
Jun 30, 2025
Treace Q2 2025 Earnings Report
Treace Medical Concepts reported its second quarter 2025 financial results, showcasing revenue growth and improved net loss and adjusted EBITDA.
Key Takeaways
Treace Medical Concepts delivered solid financial results in the second quarter of 2025, with revenue increasing by 7% year-over-year to $47.4 million. The company significantly improved its net loss by 18% and adjusted EBITDA by 58%, demonstrating progress in its strategic initiatives and expanded product portfolio.
Revenue for Q2 2025 reached $47.4 million, marking a 7% increase compared to Q2 2024.
Net loss improved by 18% to $(17.4) million in Q2 2025, down from $(21.2) million in Q2 2024.
Adjusted EBITDA improved by 58% to $(3.6) million in Q2 2025, compared to $(8.7) million in Q2 2024.
The company expanded its global patent portfolio to 117 granted patents and 163 pending patent applications.
Forward Guidance
Treace Medical Concepts reaffirmed its full-year 2025 revenue guidance and continues to expect breakeven Adjusted EBITDA for the full year.
Positive Outlook
- Reaffirming full-year 2025 revenue guidance of $224 million to $230 million.
- Expected revenue growth of 7% to 10% for full-year 2025 compared to 2024.
- Continued expectation of breakeven Adjusted EBITDA for the full-year 2025.
- Expected 50% reduction in cash used for full year 2025 compared to 2024.
- Anticipated accelerating revenue growth rates for the 2025 third and fourth quarters.
Challenges Ahead
- No specific negative forward guidance points were explicitly stated in the report.
- High variability, complexity, and low visibility for items excluded from non-GAAP Adjusted EBITDA reconciliation on a forward-looking basis.
- Potential impact of increased competition and accelerating adoption of MIS osteotomy solutions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...